Drug intelligence / Profile preview

nelfinavir + stavudine + didanosine

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules
Administration: Oral

Overview

Triple antiretroviral combination of **nelfinavir** (a protease inhibitor), **stavudine** (a nucleoside reverse transcriptase inhibitor, or NRTI), and **didanosine** (an NRTI) primarily used for the treatment of **HIV infection**. Nelfinavir inhibits HIV-1 protease, preventing viral polyprotein processing and maturation; stavudine and didanosine act as chain terminators by inhibiting HIV reverse transcriptase, blocking viral DNA synthesis. This regimen was a common early HAART (highly active antiretroviral therapy) approach, and is generally administered orally[1][2][3].

Targets

Human immunodeficiency virus type 1 reverse transcriptasePR (Progesterone receptor)

Beyond the preview

Go deeper on nelfinavir + stavudine + didanosine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nelfinavir + stavudine + didanosine.

Explore the full profile